1
|
Exner TE, Dokler J, Friedrichs S, Seitz C, Bleken FL, Friis J, Hagelien TF, Mercuri F, Costa AL, Furxhi I, Sarimveis H, Afantitis A, Marvuglia A, Larrea-Gallegos GM, Serchi T, Serra A, Greco D, Nymark P, Himly M, Wiench K, Watzek N, Schillinger EK, Gavillet J, Lynch I, Karwath A, Haywood AL, Gkoutos GV, Hischier R. Going digital to boost safe and sustainable materials innovation markets. The digital safe-and-sustainability-by-design innovation approach of the PINK project. Comput Struct Biotechnol J 2025; 29:110-124. [PMID: 40241813 PMCID: PMC12002836 DOI: 10.1016/j.csbj.2025.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2025] [Revised: 03/10/2025] [Accepted: 03/11/2025] [Indexed: 04/18/2025] Open
Abstract
In this innovation report, we present the vision of the PINK project to foster Safe-and-Sustainable-by-Design (SSbD) advanced materials and chemicals (AdMas&Chems) development by integrating state-of-the-art computational modelling, simulation tools and data resources. PINK proposes a novel approach for the use of the SSbD Framework, whose innovative approach is based on the application of a multi-objective optimisation procedure for the criteria of functionality, safety, sustainability and cost efficiency. At the core is the PINK open innovation platform, a distributed system that integrates all relevant modelling resources enriched with advanced data visualisation and an AI-driven decision support system. Data and modelling tools from the, in large parts, independently developed areas of functional design, safety assessment, life cycle assessment & costing are brought together based on a newly created Interoperability Framework. The PINK In Silico Hub, as the user Interface to the platform, finally guides the user through the complete AdMas&Chems development process from idea creation to market introduction. Guided by two Developmental Case Studies, the process of building of the PINK Platform is iterative, ensuring industry readiness to implement and apply it. Additionally, the Industrial Demonstrator programme will be introduced as part of the final project phase, which allows industry partners and especially small and medium enterprises (SMEs) to become part of the PINK consortium. Feedback from the Demonstrators as well as other stakeholder-engagement activities and collaborations will shape the platform's final look and feel and, even more important, activities to assure long-term technical sustainability.
Collapse
Affiliation(s)
- Thomas E. Exner
- Seven Past Nine d.o.o., Hribljane, Cerknica 1380, Slovenia
- Seven Past Nine GmbH., Rebacker 6, Schopfheim 79650, Germany
| | - Joh Dokler
- Seven Past Nine d.o.o., Hribljane, Cerknica 1380, Slovenia
| | | | | | | | - Jesper Friis
- SINTEF AS, Strindvegen 4, Trondheim 7034, Norway
| | | | - Francesco Mercuri
- Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), Consiglio Nazionale delle Ricerche, Via P. Gobetti 101, Bologna 40128, Italy
| | - Anna L. Costa
- Istituto di Scienza, Tecnologia e Sostenibilità per lo Sviluppo dei Materiali Ceramici. Consiglio Nationale Delle Ricerche (CNR-ISSMC), Via Granarolo 64, Faenza 48018, Italy
| | - Irini Furxhi
- Istituto di Scienza, Tecnologia e Sostenibilità per lo Sviluppo dei Materiali Ceramici. Consiglio Nationale Delle Ricerche (CNR-ISSMC), Via Granarolo 64, Faenza 48018, Italy
| | - Haralambos Sarimveis
- School of Chemical Engineering, National Technical University of Athens, 9 Heroon Polytechniou, Athens 15780, Greece
| | | | - Antonino Marvuglia
- Luxembourg Institute of Science and Technology, 5, avenue des Hauts-Fourneaux, Esch-sur-Alzette 4362, Luxembourg
| | - Gustavo M. Larrea-Gallegos
- Luxembourg Institute of Science and Technology, 5, avenue des Hauts-Fourneaux, Esch-sur-Alzette 4362, Luxembourg
| | - Tommaso Serchi
- Luxembourg Institute of Science and Technology, 5, avenue des Hauts-Fourneaux, Esch-sur-Alzette 4362, Luxembourg
| | - Angela Serra
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki 00790, Finland
| | - Dario Greco
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki 00790, Finland
| | - Penny Nymark
- Institute for Environmental Medicine, Karolinska Institutet, Nobels Väg 5, Stockholm 17177, Sweden
| | - Martin Himly
- Department of Biosciences & Medical Biology, Paris Lodron Universität Salzburg, Hellbrunnerstrasse 34, Salzburg 5020, Austria
| | - Karin Wiench
- BASF SE, Carl Bosch Str. 38, Ludwigshafen am Rhein 67056, Germany
| | - Nico Watzek
- BASF SE, Carl Bosch Str. 38, Ludwigshafen am Rhein 67056, Germany
| | | | - Jérôme Gavillet
- Innovative Advanced Materials Initiative, Rue de Ransbeek 310, Bruxelles 1120, Belgium
| | - Iseult Lynch
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
- Centre for Environmental Research and Justice, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - Andreas Karwath
- Department of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
- Centre for Health Data Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - Alexe L. Haywood
- Department of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
- Centre for Health Data Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - Georgios V. Gkoutos
- Centre for Environmental Research and Justice, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
- Department of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
- Centre for Health Data Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - Roland Hischier
- Advancing Life Cycle Assessment Group, Swiss Federal Laboratories for Materials Science and Technology, Lerchenfeldstrasse 5, St. Gallen 9014, Switzerland
| |
Collapse
|
2
|
Punz B, Brajnik M, Dokler J, Amos JD, Johnson L, Reilly K, Papadiamantis AG, Green Etxabe A, Walker L, Martinez DST, Friedrichs S, Weltring KM, Günday-Türeli N, Svendsen C, Ogilvie Hendren C, Wiesner MR, Himly M, Lynch I, Exner TE. Instance maps as an organising concept for complex experimental workflows as demonstrated for (nano)material safety research. BEILSTEIN JOURNAL OF NANOTECHNOLOGY 2025; 16:57-77. [PMID: 39877837 PMCID: PMC11773194 DOI: 10.3762/bjnano.16.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Accepted: 11/27/2024] [Indexed: 01/31/2025]
Abstract
Nanosafety assessment, which seeks to evaluate the risks from exposure to nanoscale materials, spans materials synthesis and characterisation, exposure science, toxicology, and computational approaches, resulting in complex experimental workflows and diverse data types. Managing the data flows, with a focus on provenance (who generated the data and for what purpose) and quality (how was the data generated, using which protocol with which controls), as part of good research output management, is necessary to maximise the reuse potential and value of the data. Instance maps have been developed and evolved to visualise experimental nanosafety workflows and to bridge the gap between the theoretical principles of FAIR (Findable, Accessible, Interoperable and Re-usable) data and the everyday practice of experimental researchers. Instance maps are most effective when applied at the study design stage to associate the workflow with the nanomaterials, environmental conditions, method descriptions, protocols, biological and computational models to be used, and the data flows arising from study execution. Application of the InstanceMaps tool (described herein) to research workflows of increasing complexity is presented to demonstrate its utility, starting from (i) documentation of a nanomaterial's synthesis, functionalisation, and characterisation, over (ii) assessment of a nanomaterial's transformations in complex media, (iii) description of the culturing of ecotoxicity model organisms Daphnia magna and their use in standardised tests for nanomaterials ecotoxicity assessment, and (iv) visualisation of complex workflows in human immunotoxicity assessment using cell lines and primary cellular models, to (v) the use of the instance map approach for the coordination of materials and data flows in complex multipartner collaborative projects and for the demonstration of case studies. Finally, areas for future development of the instance map approach and the tool are highlighted.
Collapse
Affiliation(s)
- Benjamin Punz
- Department of Biosciences & Medical Biology, Paris Lodron University of Salzburg, Hellbrunnerstrasse 34, 5020 Salzburg, Austria
| | - Maja Brajnik
- Seven Past Nine d.o.o., Hribljane 10, 1380 Cerknica, Slovenia
| | - Joh Dokler
- Seven Past Nine d.o.o., Hribljane 10, 1380 Cerknica, Slovenia
| | - Jaleesia D Amos
- Center for the Environmental Implications of Nano Technology (CEINT), Civil & Environmental Engineering, Duke University, Durham, North Carolina, 2770y8, USA
| | - Litty Johnson
- Department of Biosciences & Medical Biology, Paris Lodron University of Salzburg, Hellbrunnerstrasse 34, 5020 Salzburg, Austria
| | - Katie Reilly
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, B15 2TT Birmingham, United Kingdom
| | - Anastasios G Papadiamantis
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, B15 2TT Birmingham, United Kingdom
| | - Amaia Green Etxabe
- UK Centre for Ecology and Hydrology, Pollution, Wallingford, Oxfordshire, United Kingdom
| | - Lee Walker
- UK Centre for Ecology and Hydrology, Pollution, Wallingford, Oxfordshire, United Kingdom
| | - Diego S T Martinez
- Brazilian Nanotechnology National Laboratory (LNNano), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, Sao Paulo, Brazil
| | | | - Klaus M Weltring
- Gesellschaft für Bioanalytik Münster, Mendelstraße 17, 48149 Münster, Germany
| | | | - Claus Svendsen
- UK Centre for Ecology and Hydrology, Pollution, Wallingford, Oxfordshire, United Kingdom
| | | | - Mark R Wiesner
- Center for the Environmental Implications of Nano Technology (CEINT), Civil & Environmental Engineering, Duke University, Durham, North Carolina, 2770y8, USA
| | - Martin Himly
- Department of Biosciences & Medical Biology, Paris Lodron University of Salzburg, Hellbrunnerstrasse 34, 5020 Salzburg, Austria
| | - Iseult Lynch
- School of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, B15 2TT Birmingham, United Kingdom
| | - Thomas E Exner
- Seven Past Nine GmbH, Rebacker 68, 79650 Schopfheim, Germany
- Seven Past Nine d.o.o., Hribljane 10, 1380 Cerknica, Slovenia
| |
Collapse
|
3
|
Öztemiz Topcu E, Gadermaier G. To stay or not to stay intact as an allergen: the endolysosomal degradation assay used as tool to analyze protein immunogenicity and T cell epitopes. FRONTIERS IN ALLERGY 2024; 5:1440360. [PMID: 39071040 PMCID: PMC11272489 DOI: 10.3389/falgy.2024.1440360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Accepted: 06/25/2024] [Indexed: 07/30/2024] Open
Abstract
Antigen uptake and processing of exogenous proteins is critical for adaptive immunity, particularly for T helper cell activation. Proteins undergo distinct proteolytic processing in endolysosomal compartments of antigen-presenting cells. The resulting peptides are presented on MHC class II molecules and specifically recognized by T cells. The in vitro endolysosomal degradation assay mimics antigen processing by incubating a protein of interest with a protease cocktail derived from the endolysosomal compartments of antigen presenting cells. The kinetics of protein degradation is monitored by gel electrophoresis and allows calculation of a protein's half-life and thus endolysosomal stability. Processed peptides are analyzed by mass spectrometry and abundant peptide clusters are shown to harbor T cell epitopes. The endolysosomal degradation assay has been widely used to study allergens, which are IgE-binding proteins involved in type I hypersensitivity. In this review article, we provide the first comprehensive overview of the endolysosomal degradation of 29 isoallergens and variants originating from the PR-10, Ole e 1-like, pectate lyase, defensin polyproline-linked, non-specific lipid transfer, mite group 1, 2, and 5, and tropomyosin protein families. The assay method is described in detail and suggestions for improved standardization and reproducibility are provided. The current hypothesis implies that proteins with high endolysosomal stability can induce an efficient immune response, whereas highly unstable proteins are degraded early during antigen processing and therefore not efficient for MHC II peptide presentation. To validate this concept, systematic analyses of high and low allergenic representatives of protein families should be investigated. In addition to purified molecules, allergen extracts should be degraded to analyze potential matrix effects and gastrointestinal proteolysis of food allergens. In conclusion, individual protein susceptibility and peptides obtained from the endolysosomal degradation assay are powerful tools for understanding protein immunogenicity and T cell reactivity. Systematic studies and linkage with in vivo sensitization data will allow the establishment of (machine-learning) tools to aid prediction of immunogenicity and allergenicity. The orthogonal method could in the future be used for risk assessment of novel foods and in the generation of protein-based immunotherapeutics.
Collapse
|
4
|
Johnson L, Aglas L, Punz B, Dang HH, Christ C, Pointner L, Wenger M, Hofstaetter N, Hofer S, Geppert M, Andosch A, Ferreira F, Horejs-Hoeck J, Duschl A, Himly M. Mechanistic insights into silica nanoparticle-allergen interactions on antigen presenting cell function in the context of allergic reactions. NANOSCALE 2023; 15:2262-2275. [PMID: 36630186 PMCID: PMC9893438 DOI: 10.1039/d2nr05181h] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 11/30/2022] [Indexed: 06/17/2023]
Abstract
The incorporation of nanomaterials into consumer products has substantially increased in recent years, raising concerns about their safety. The inherent physicochemical properties of nanoparticles allow them to cross epithelial barriers and gain access to immunocompetent cells. Nanoparticles in cosmetic products can potentially interact with environmental allergens, forming a protein corona, and together penetrate through damaged skin. Allergen-nanoparticle interactions may influence the immune response, eventually resulting in an adverse or beneficial outcome in terms of allergic reactivity. This study determines the impact of silica nanoparticle-allergen interactions on allergic sensitization by studying the major molecular mechanisms affecting allergic responses. The major birch pollen allergen Bet v 1 was chosen as a model allergen and the birch pollen extract as a comparator. Key events in immunotoxicity including allergen uptake, processing, presentation, expression of costimulatory molecules and cytokine release were studied in human monocyte-derived dendritic cells. Using an in vivo sensitization model, murine Bet v 1-specific IgG and IgE levels were monitored. Upon the interaction of allergens with silica nanoparticles, we observed an enhanced uptake of the allergen by macropinocytosis, improved proteolytic processing, and presentation concomitant with a propensity to increase allergen-specific IgG2a and decrease IgE antibody levels. Together, these events suggest that upon nanoparticle interactions the immune response is biased towards a type 1 inflammatory profile, characterized by the upregulation of T helper 1 (Th1) cells. In conclusion, the interaction of the birch pollen allergen with silica nanoparticles will not worsen allergic sensitization, a state of type 2-inflammation, but rather seems to decrease it by skewing towards a Th1-dominated immune response.
Collapse
Affiliation(s)
- Litty Johnson
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Lorenz Aglas
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Benjamin Punz
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Hieu-Hoa Dang
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Constantin Christ
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Lisa Pointner
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Mario Wenger
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Norbert Hofstaetter
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Sabine Hofer
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Mark Geppert
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Ancuela Andosch
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Fatima Ferreira
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Jutta Horejs-Hoeck
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Albert Duschl
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| | - Martin Himly
- Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
| |
Collapse
|
5
|
Punz B, Johnson L, Geppert M, Dang HH, Horejs-Hoeck J, Duschl A, Himly M. Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms. Pharmaceutics 2022; 14:pharmaceutics14051103. [PMID: 35631689 PMCID: PMC9146724 DOI: 10.3390/pharmaceutics14051103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 05/17/2022] [Accepted: 05/18/2022] [Indexed: 11/16/2022] Open
Abstract
Silica nanoparticles (SiNPs) are generally regarded as safe and may represent an attractive carrier platform for nanomedical applications when loaded with biopharmaceuticals. Surface functionalization by different chemistries may help to optimize protein loading and may further impact uptake into the targeted tissues or cells, however, it may also alter the immunologic profile of the carrier system. In order to circumvent side effects, novel carrier candidates need to be tested thoroughly, early in their development stage within the pharmaceutical innovation pipeline, for their potential to activate or modify the immune response. Previous studies have identified surface functionalization by different chemistries as providing a plethora of modifications for optimizing efficacy of biopharmaceutical (nano)carrier platforms while maintaining an acceptable safety profile. In this study, we synthesized SiNPs and chemically functionalized them to obtain different surface characteristics to allow their application as a carrier system for allergen-specific immunotherapy. In the present study, crude natural allergen extracts are used in combination with alum instead of well-defined active pharmaceutical ingredients (APIs), such as recombinant allergen, loaded onto (nano)carrier systems with immunologically inert and stable properties in suspension. This study was motivated by the hypothesis that comparing different charge states could allow tailoring of the binding capacity of the particulate carrier system, and hence the optimization of biopharmaceutical uptake while maintaining an acceptable safety profile, which was investigated by determining the maturation of human antigen-presenting cells (APCs). The functionalized nanoparticles were characterized for primary and hydrodynamic size, polydispersity index, zeta potential, endotoxin contamination. As potential candidates for allergen-specific immunotherapy, the differently functionalized SiNPs were non-covalently coupled with a highly purified, endotoxin-free recombinant preparation of the major birch pollen allergen Bet v 1 that functioned for further immunological testing. Binding efficiencies of allergen to SiNPs was controlled to determine uptake of API. For efficacy and safety assessment, we employed human monocyte-derived dendritic cells as model for APCs to detect possible differences in the particles’ APC maturation potential. Functionalization of SiNP did not affect the viability of APCs, however, the amount of API physisorbed onto the nanocarrier system, which induced enhanced uptake, mainly by macropinocytosis. We found slight differences in the maturation state of APCs for the differently functionalized SiNP–API conjugates qualifying surface functionalization as an effective instrument for optimizing the immune response towards SiNPs. This study further suggests that surface-functionalized SiNPs could be a suitable, immunologically inert vehicle for the efficient delivery of biopharmaceutical products, as evidenced here for allergen-specific immunotherapy.
Collapse
|
6
|
Hofer S, Hofstätter N, Punz B, Hasenkopf I, Johnson L, Himly M. Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2022; 14:e1804. [PMID: 36416020 PMCID: PMC9787548 DOI: 10.1002/wnan.1804] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 03/24/2022] [Accepted: 03/30/2022] [Indexed: 11/24/2022]
Abstract
Nanosafety assessment has experienced an intense era of research during the past decades driven by a vivid interest of regulators, industry, and society. Toxicological assays based on in vitro cellular models have undergone an evolution from experimentation using nanoparticulate systems on singular epithelial cell models to employing advanced complex models more realistically mimicking the respective body barriers for analyzing their capacity to alter the immune state of exposed individuals. During this phase, a number of lessons were learned. We have thus arrived at a state where the next chapters have to be opened, pursuing the following objectives: (1) to elucidate underlying mechanisms, (2) to address effects on vulnerable groups, (3) to test material mixtures, and (4) to use realistic doses on (5) sophisticated models. Moreover, data reproducibility has become a significant demand. In this context, we studied the emerging concept of adverse outcome pathways (AOPs) from the perspective of immune activation and modulation resulting in pro-inflammatory versus tolerogenic responses. When considering the interaction of nanomaterials with biological systems, protein corona formation represents the relevant molecular initiating event (e.g., by potential alterations of nanomaterial-adsorbed proteins). Using this as an example, we illustrate how integrated experimental-computational workflows combining in vitro assays with in silico models aid in data enrichment and upon comprehensive ontology-annotated (meta)data upload to online repositories assure FAIRness (Findability, Accessibility, Interoperability, Reusability). Such digital twinning may, in future, assist in early-stage decision-making during therapeutic development, and hence, promote safe-by-design innovation in nanomedicine. Moreover, it may, in combination with in silico-based exposure-relevant dose-finding, serve for risk monitoring in particularly loaded areas, for example, workplaces, taking into account pre-existing health conditions. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.
Collapse
Affiliation(s)
- Sabine Hofer
- Division of Allergy & Immunology, Department of Biosciences & Medical BiologyParis Lodron University of SalzburgSalzburgAustria
| | - Norbert Hofstätter
- Division of Allergy & Immunology, Department of Biosciences & Medical BiologyParis Lodron University of SalzburgSalzburgAustria
| | - Benjamin Punz
- Division of Allergy & Immunology, Department of Biosciences & Medical BiologyParis Lodron University of SalzburgSalzburgAustria
| | - Ingrid Hasenkopf
- Division of Allergy & Immunology, Department of Biosciences & Medical BiologyParis Lodron University of SalzburgSalzburgAustria
| | - Litty Johnson
- Division of Allergy & Immunology, Department of Biosciences & Medical BiologyParis Lodron University of SalzburgSalzburgAustria
| | - Martin Himly
- Division of Allergy & Immunology, Department of Biosciences & Medical BiologyParis Lodron University of SalzburgSalzburgAustria
| |
Collapse
|